Clinical Research Directory
Browse clinical research sites, groups, and studies.
Registry of Autoimmune Interstitial Lung Disease
Sponsor: EPIMAR registry
Summary
Interstitial lung diseases (ILD) constitute a group of entities characterized by inflammation and/or fibrosis of the lung parenchyma. In recent years, with the advent of new diagnostic tools and therapeutic options, multidisciplinary evaluation is essential, since it optimizes the interpretation of each case and the quality of care for these pathologies Consensus for the identification and management of ILD associated with SSc (ILD-SSc) is the only guideline published at present. In the others autoimmune ILD (Ai-ILD), screening, diagnosis, treatment and follow-up strategies are usually performed according to the criteria of the treating medical team. Guidelines regarding the follow-up and indication of immunosuppressive and antifibrotic treatment are lacking. Many questions on the horizon of the Ai-ILD should be answered as better quality evidence emerges from studies with a greater number of patients and better methodological design.
Official title: Characteristics of Patients With Autoimmune Interstitial Lund Disease From Argentina
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
OBSERVATIONAL
Enrollment
1000
Start Date
2022-04-10
Completion Date
2027-10
Last Updated
2022-05-06
Healthy Volunteers
No
Interventions
Multidisciplinary aproach
regular tests
Locations (1)
Epimar Ii
Buenos Aires, Argentina